# Clear.bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/clear-bio

- Industry: Healthcare IT
- Headquarters: Amsterdam, Netherlands
- Website: www.clear.bio
- Total disclosed funding: $0.9M
- Latest round: Seed (Feb 25, 2020)
- Investors on record: 2

## About

Clear.bio provides a digital health solution designed for individuals with type 2 diabetes, integrating glucose monitoring, mobile technology, and dietary coaching to promote healthier lifestyles.Founded in 2019 and headquartered in Amsterdam, Netherlands, Clear.bio specializes in diabetes management through technology-driven solutions.  The company is co-founded by Madelon Bracke, Piet Van Dam, Rebecca Waasdorp-Morris, and Tony Bfa-de, with Piet Van Dam serving as CEO.Clear.bio specializes in providing a comprehensive digital health solution aimed at individuals with type 2 diabetes. Their core offering includes a personalized treatment program that utilizes a combination of a glucose sensor, a mobile application, and coaching by dietitians. This service enables users to monitor their blood glucose levels and understand the impact of their dietary choices on their health. The Clear.bio approach emphasizes reversing type 2 diabetes through nutritional adjustments, allowing users to achieve stable glucose levels, reduce medication needs, and improve overall health within a structured 12-week timeframe. The company serves a diverse customer base, primarily located in European markets, where it has garnered attention from individuals seeking effective, lifestyle-based solutions to manage their diabetes.Clear.bio's revenue for the most recent year, 2023, was EUR 39,174, with an EBITDA of EUR -55,757.4. Their revenue model is based on a subscription approach for treatment services, which includes access to a mobile app and personalized coaching. In September 2025, Clear.bio raised EUR 1.7 million in venture funding from new investors Horizon Flevoland and Invest International. Returning investor Future Food Fund and individual investors also participated in the round. Customers typically engage with the service by subscribing to a package that includes the necessary tools for monitoring and adjusting their dietary habits to manage diabetes effectively. The company may also engage in partnerships with health insurers to facilitate reimbursement where applicable. The company plans to utilize the September 2025 funding to grow its digital program for diabetes remission in the Netherlands and to obtain insurance coverage in both France and Germany.

## Funding rounds

- Seed, Feb 25, 2020, $0.9M — Antler, Healthy.Capital

## Investors

- Antler (https://capitalatlas.ai/funds/antler) — Seed
- Healthy.Capital (https://capitalatlas.ai/funds/healthy-capital) — Seed